Health­care gi­ant Gri­fols ac­cused of ma­nip­u­lat­ing fi­nances by short sell­er Gotham City, stock plum­mets 

Plas­ma-de­rived med­i­cines man­u­fac­tur­ing com­pa­ny Gri­fols has been ac­cused of ma­nip­u­lat­ing its re­port­ed debt and EBIT­DA by UK-based hedge fund Gotham City Re­search, caus­ing its stock $GRFS to plum­met by about 20% on Tues­day af­ter­noon.

The Span­ish health­care gi­ant said Gotham City’s al­le­ga­tions were “false in­for­ma­tion and spec­u­la­tions” in an SEC fil­ing on Tues­day.

“As a com­pa­ny com­mit­ted to trans­paren­cy, in­tegri­ty, and eth­i­cal con­duct, we cat­e­gor­i­cal­ly de­ny and re­ject any al­le­ga­tions of wrong­ful ac­count­ing or re­port­ing prac­tices of our con­sol­i­dat­ed fi­nan­cial state­ments,” Gri­fols said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER